Monitoring the dissolution mechanisms of amorphous bicalutamide solid dispersions via real-time Raman mapping

Molecular Pharmaceutics

Volumn 12, Issue 5, 2015, Pages 1512-1522

  Tres, Francesco ^a   Patient, Jamie D ^a   Williams, Philip M ^a   Treacher, Kevin ^b   Booth, Jonathan ^b   Hughes, Leslie P ^b   Wren, Stephen A C ^b   Aylott, Jonathan W ^a   Burley, Jonathan C ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

amorphous solid dispersions; bicalutamide; dissolution; kinetic modeling; multivariate curve resolution; polymorphic changes; poorly soluble drugs; Raman mapping; solid state transformations; spatial correlations

Indexed keywords

ALPRENOLOL; BICALUTAMIDE; POLYMER; ANILIDE; NITRILE; TOLUENESULFONIC ACID DERIVATIVE;

ARTICLE; CRYSTALLIZATION; DISPERSION; DRUG CONFORMATION; DRUG MONITORING; DRUG SOLUBILITY; FLUORESCENCE IMAGING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; HYDROPHOBICITY; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAMAN SPECTROMETRY; SOLID STATE; SURFACE AREA; TEMPERATURE; CHEMISTRY; KINETICS; POWDER DIFFRACTION; SOLUBILITY;

ANILIDES; CRYSTALLIZATION; KINETICS; NITRILES; POWDER DIFFRACTION; SOLUBILITY; SPECTRUM ANALYSIS, RAMAN; TOSYL COMPOUNDS;

EID: 84929168991     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500829v     Document Type: Article

References (46)

1. Babu, N. J.; Nangia, A. Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals Cryst. Growth Des. 2011, 11, 2662-2679
2. Hancock, B. C.; Parks, M. What is the True Solubility Advantage for Amorphous Pharmaceuticals? Pharm. Res. 2000, 17, 397-404
3. Hancock, B. C.; Zografi, G. Characteristics and significance of the amorphous state in pharmaceutical systems J. Pharm. Sci. 1997, 86, 1-12
4. Murdande, S. B.; Pikal, M. J.; Shanker, R. M.; Bogner, R. H. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis J. Pharm. Sci. 2010, 99, 1254-1264
5. Greenhalgh, D. J.; Williams, A. C.; Timmins, P.; York, P. Solubility parameters as predictors of miscibility in solid dispersions J. Pharm. Sci. 1999, 88, 1182-1190
6. Marsac, P. J.; Shamblin, S. L.; Taylor, L. S. Theoretical and Practical Approaches for Prediction of Drug-Polymer Miscibility and Solubility Pharm. Res. 2006, 23, 2417-2426
7. Leuner, C.; Dressman, J. Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 2000, 50, 47-60
8. Serajuddin, A. T. M. Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs J. Pharm. Sci. 1999, 88, 1058-1066
9. Yang, J.; Grey, K.; Doney, J. An improved kinetics approach to describe the physical stability of amorphous solid dispersions Int. J. Pharm. 2010, 384, 24-31
10. Ivanisevic, I. Physical stability studies of miscible amorphous solid dispersions J. Pharm. Sci. 2010, 99, 4005-4012
11. Langham, Z. A.; Booth, J.; Hughes, L. P.; Reynolds, G. K.; Wren, S. A. C. Mechanistic insights into the dissolution of spray-dried amorphous solid dispersions J. Pharm. Sci. 2012, 101, 2798-2810
12. Tres, F.; Treacher, K.; Booth, J.; Hughes, L. P.; Wren, S. A. C.; Aylott, J. W.; Burley, J. C. Real time Raman imaging to understand dissolution performance of amorphous solid dispersions J. Controlled Release 2014, 188, 53-60
13. Craig, D. Q. M. The mechanisms of drug release from solid dispersions in water-soluble polymers Int. J. Pharm. 2002, 231, 131-144
14. Alonzo, D. E.; Zhang, G. G. Z.; Zhou, D.; Gao, Y.; Taylor, L. S. Understanding the Behavior of Amorphous Pharmaceutical Systems during Dissolution Pharm. Res. 2010, 27, 608-618
15. Tho, I.; Liepold, B.; Rosenberg, J.; Maegerlein, M.; Brandl, M.; Fricker, G. Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media Eur. J. Pharm. Sci. 2010, 40, 25-32
16. Karavas, E.; Ktistis, G.; Xenakis, A.; Georgarakis, E. Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone Eur. J. Pharm. Biopharm. 2006, 63, 103-114
17. Gray, V.; Kelly, G.; Xia, M.; Butler, C.; Thomas, S.; Mayock, S. The Science of USP 1 and 2 Dissolution: Present Challenges and Future Relevance Pharm. Res. 2009, 26, 1289-1302
18. Pygall, S. R.; Whetstone, J.; Timmins, P.; Melia, C. D. Pharmaceutical applications of confocal laser scanning microscopy: The physical characterisation of pharmaceutical systems Adv. Drug Delivery Rev. 2007, 59, 1434-1452
19. van der Weerd, J.; Kazarian, S. G. Release of poorly soluble drugs from HPMC tablets studied by FTIR imaging and flow-through dissolution tests J. Pharm. Sci. 2005, 94, 2096-2109
20. Wray, P. S.; Clarke, G. S.; Kazarian, S. G. Dissolution of tablet-in-tablet formulations studied with ATR-FTIR spectroscopic imaging Eur. J. Pharm. Sci. 2013, 48, 748-757
21. Avalle, P.; Pygall, S. R.; Gower, N.; Midwinter, A. The use of in situ near infrared spectroscopy to provide mechanistic insights into gel layer development in HPMC hydrophilic matrices Eur. J. Pharm. Sci. 2011, 43, 400-408
22. Avalle, P.; Pygall, S. R.; Pritchard, J.; Jastrzemska, A. Interrogating erosion-based drug liberation phenomena from hydrophilic matrices using near infrared (NIR) spectroscopy Eur. J. Pharm. Sci. 2013, 48, 72-79
23. Chen, Y. Y.; Hughes, L. P.; Gladden, L. F.; Mantle, M. D. Quantitative ultra-fast MRI of HPMC swelling and dissolution J. Pharm. Sci. 2010, 99, 3462-3472
24. Richardson, J. C.; Bowtell, R. W.; Mäder, K.; Melia, C. D. Pharmaceutical applications of magnetic resonance imaging (MRI) Adv. Drug Delivery Rev. 2005, 57, 1191-1209
25. Chan, K. L. A.; Kazarian, S. G. FTIR Spectroscopic Imaging of Dissolution of a Solid Dispersion of Nifedipine in Poly(ethylene glycol) Mol. Pharmaceutics 2004, 1, 331-335
26. Windbergs, M.; Haaser, M.; McGoverin, C. M.; Gordon, K. C.; Kleinebudde, P.; Strachan, C. J. Investigating the relationship between drug distribution in solid lipid matrices and dissolution behaviour using Raman spectroscopy and mapping J. Pharm. Sci. 2010, 99, 1464-1475
27. Haaser, M.; Windbergs, M.; McGoverin, C. M.; Kleinebudde, P.; Rades, T.; Gordon, K. C.; Strachan, C. J. Analysis of matrix dosage forms during dissolution testing using raman microscopy J. Pharm. Sci. 2011, 100, 4452-4459
28. Fussell, A.; Garbacik, E.; Offerhaus, H.; Kleinebudde, P.; Strachan, C. In situ dissolution analysis using coherent anti-Stokes Raman scattering (CARS) and hyperspectral CARS microscopy Eur. J. Pharm. Biopharm. 2013, 85, 1141-1147
29. Brillante, A.; Bilotti, I.; della Valle, R. G.; Venuti, E.; Girlando, A. Probing polymorphs of organic semiconductors by lattice phonon Raman microscopy CrystEngComm 2008, 10, 937-946
30. Al-Dulaimi, S.; Aina, A.; Burley, J. C. Rapid polymorph screening on milligram quantities of pharmaceutical material using phonon-mode Raman spectroscopy CrystEngComm 2010, 12, 1038-1040
31. Abu-Diak, O. A.; Jones, D. S.; Andrews, G. P. Understanding the performance of melt-extruded poly(ethylene oxide)-bicalutamide solid dispersions: Characterisation of microstructural properties using thermal, spectroscopic and drug release methods J. Pharm. Sci. 2012, 101, 200-213
32. Andrews, G. P.; AbuDiak, O. A.; Jones, D. S. Physicochemical characterization of hot melt extruded bicalutamide-polyvinylpyrrolidone solid dispersions J. Pharm. Sci. 2010, 99, 1322-1335
33. Német, Z.; Sztatisz, J.; Demeter, A. Polymorph transitions of bicalutamide: A remarkable example of mechanical activation J. Pharm. Sci. 2008, 97, 3222-3232
34. Vega, D. R.; Polla, G.; Martinez, A.; Mendioroz, E.; Reinoso, M. Conformational polymorphism in bicalutamide Int. J. Pharm. 2007, 328, 112-118
35. Breitenbach, J. Melt extrusion can bring new benefits to HIV therapy Am. J. Drug Delivery 2006, 4, 61-64
36. United States Pharmacopoeia 31 and National Formulary 26; The United States Pharmacopeial Convention, Inc.: Rockville, Md, 2008.
37. Westheim, R. Bicalutamide forms. U.S. Patent 20040063782, 2004.
38. European Pharmacopoeia, 6 th ed.; Directorate for the Quality of Medicines and Healthcare of the Council of Europe: Strasbourg, France, 2008.
39. R Development Core Team. R: A language and environment for statistical computing; R Foundation for Statistical Computing: Vienna, Austria, 2011.
40. Gendrin, C.; Roggo, Y.; Collet, C. Pharmaceutical applications of vibrational chemical imaging and chemometrics: A review J. Pharm. Biomed. Anal. 2008, 48, 533-553
41. Gallagher, N. B.; Shaver, J. M.; Martin, E. B.; Morris, J.; Wise, B. M.; Windig, W. Curve resolution for multivariate images with applications to TOF-SIMS and Raman Chemometr. Intell. Lab. Syst. 2004, 73, 105-117
42. Duponchel, L.; Elmi-Rayaleh, W.; Ruckebusch, C.; Huvenne, J. P. Multivariate Curve Resolution Methods in Imaging Spectroscopy: Influence of Extraction Methods and Instrumental Perturbations J. Chem. Inf. Comput. Sci. 2003, 43, 2057-2067
43. Awa, K.; Okumura, T.; Shinzawa, H.; Otsuka, M.; Ozaki, Y. Self-modeling curve resolution (SMCR) analysis of near-infrared (NIR) imaging data of pharmaceutical tablets Anal. Chim. Acta 2008, 619, 81-86
44. Rutan, S.; de Juan, A.; Tauler, R. Introduction to Multivariate Curve Resolution. Comprehensive Chemometrics; Elsevier: Oxford, 2009; Vol. 2, Chapter 2.15, pp 249-259.
45. de Juan, A.; Rutan, S.; Tauler, R. Two-Way Data Analysis: Multivariate Curve Resolution-Iterative Resolution Methods. Comprehensive Chemometrics; Elsevier: Oxford, 2009; Vol. 2, Chapter 2.19, pp 325-344.
46. Snyder, V.; Alkemper, J.; Voorhees, P. The development of spatial correlations during Ostwald ripening: a test of theory Acta Mater. 2000, 48, 2689-2701